Skip to main content

Table 2 Co-medication with methotrexate or prednisone with etanercept

From: Reduction in the utilization of prednisone or methotrexate in Canadian claims data following initiation of etanercept in pediatric patients with juvenile idiopathic arthritis

Methotrexate Co-Therapy Study Patients (N = 330)
Received no co-medication before or in the 12 months after ETN initiation 222 (67%)
Received co-medication with MTX before ETN initiation 103 (31%)
 Stopped MTX when ETN was initiated 18
 Continued MTX for 12 months after ETN initiation 85
Started MTX co-medication after ETN was initiated 3* (2%)
Prednisone Co-Therapy Study Patients (N = 330)
Received no co-medication before or in the 12 months after ETN initiation 223 (68%)
Received co-medication with PRD before ETN initiation 92 (28%)
 Stopped PRD when ETN was initiated 46
 Continued PRD for 12 months after ETN initiation 46
Started PRN co-medication after ETN was initiated 15 (5%)
  1. *Groups with less than 6 patients/claims were adjusted to 3 to maintain privacy
  2. ETN, etanercept; MTX, methotrexate; PRD, prednisone